Quantcast
Last updated on April 16, 2014 at 6:35 EDT

Latest Brain natriuretic peptide Stories

2014-02-18 08:31:03

- Statistically significant and durable reductions in troponin and NT-proBNP SAN DIEGO, Feb. 18, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced new data from its randomized, placebo-controlled, nonclinical study of MST-188 (low dose and high dose) in a model of chronic heart failure. The Company previously announced that a single, two-hour infusion of MST-188 improved left ventricular systolic function that was significant immediately (at the end of MST-188...

2013-07-03 10:41:39

Among patients at risk of heart failure, collaborative care based on screening for certain levels of brain-type natriuretic peptide reduced the combined rates of left ventricular systolic dysfunction, diastolic dysfunction, and heart failure as well as emergency cardiovascular hospitalizations, according to a study in the July 3 issue of JAMA. "The increasing prevalence of heart failure [HF] remains a major public health concern underlining the need for an effective prevention strategy....

2013-04-29 08:26:39

MINNEAPOLIS, April 29, 2013 /PRNewswire/ -- CVRx, Inc., a private medical device company, announced the first patient enrolled in the Barostim HOPE4HF clinical trial. The study is evaluating the effectiveness and safety of CVRx's Barostim neo in heart failure patients. Dr. Richard Abben, Director of Cardiac Intervention, with the Cardiovascular Institute of the South, in Houma, Louisiana is the Principal Investigator for the center. The prospective, randomized and controlled study will enroll...

2013-04-23 08:35:35

WALTHAM, Mass., April 23, 2013 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a leading provider of near-patient diagnostics and health information solutions, is pleased to announce the final results of the HABIT pilot study, which were recently published in the Journal of the American College of Cardiology. Led by Dr. Alan Maisel, Professor of Medicine at the University of California, San Diego, the study is the first to capture serial data from patients at high risk for recurrent acute clinical...

2013-04-18 04:21:32

GHENT, Belgium, April 18, 2013 /PRNewswire/ -- Two independent validation studies demonstrate that Pronota's biomarker CD146 significantly improves the diagnosis of acute heart failure for patients with shortness of breath. The biomarker, measured in blood, provides clinicians with unique additional information allowing better treatment of this challenging group of patients. Current diagnosis for acute heart failure is limited Current clinical practice for triaging...

2012-08-27 19:49:16

Efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in patients with heart failure and preserved ejection fraction The novel angiotensin receptor neprilysin inhibitor, LCZ696, demonstrated beneficial effects in heart failure patients with preserved ejection fraction (HFpEF), according to results of the PARAMOUNT (Prospective compArison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion) trial. Approximately half of all heart...

2011-10-26 09:09:23

Using Mendelian randomization, Roman Pfister of the University of Cambridge, UK and colleagues demonstrate a potentially causal link between low levels of B-type natriuretic peptide (BNP), a hormone released by damaged heart tissue, and the development of type 2 diabetes. The findings, published in this week's PLoS Medicine, suggest that BNP may be a potential target for interventions designed to prevent type 2 diabetes, particularly since the feasibility of altering BNP levels with drugs has...

2011-10-04 10:12:00

WALTHAM, Mass., Oct. 4, 2011 /PRNewswire/ -- At the Heart Failure Society of America's 15th Annual Scientific Meeting, Alan Maisel, M.D., VA San Diego Healthcare System, announced that B-type natriuretic peptide (BNP) may have utility in monitoring heart failure patients for early warning signs of decompensation in advance of acute presentations. HABIT, a multi-center study led by Maisel and sponsored by Alere Inc., is the first of its kind to have heart failure patients measure their...

2011-05-24 22:45:52

Elderly patients with symptoms of heart failure and increased concentrations in the blood of the biomarker copeptin, or a combination of elevated concentrations of copeptin and the biomarker NT-proBNP, had an associated increased risk of all-cause death, according to a study in the May 25 issue of JAMA. "A central part in evaluation of elderly patients with symptoms of heart failure is to identify simple tools that can aid the clinician in identifying high-risk and low-risk patients....

2011-05-05 09:57:00

BALTIMORE, May 5, 2011 /PRNewswire/ -- A substance secreted by the heart that is associated with congestive heart failure and renal failure is not predictive of reduction in systolic blood pressure in patients treated with renal artery stenting, according to results from the HERCULES trial presented as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore. The HERCULES trial is a prospective,...